IAMA Therapeutics to Unveil IAMA‑6 at ACS Spring 2025 “First‑Time Disclosures” Session

San Diego, CA – March 26, 2025 — On Wednesday, March 26 at 2:35 p.m. PDT, Marco Borgogno, PhD, Head of Discovery at IAMA Therapeutics, will present the first public data on our investigational compound IAMA‑6 during the MEDI First‑Time Disclosures session at ACS Spring 2025 (#ACSSpring2025).

IAMA‑6 is our lead clinical candidate designed to restore inhibitory neurotransmission in neurodevelopmental disorders such as autism spectrum disorder and Fragile X syndrome. Dr. Borgogno will share key pre‑clinical findings, pharmacological profile, and the roadmap toward first‑in‑human studies.